Colorectal tumors
1 paper5 findings
- Humans1
Associations
5TyG-related indices
mixedin humans1
1 study
TyG-related indices
mixedin humans1
TyG-related indices predict colorectal tumors in humans (AUCs 0.767–0.786 in CHARLS; 0.570–0.587 in NHANES).
“ROC analyses showed moderate discrimination in CHARLS (AUCs 0.767–0.786) and lower performance in NHANES (AUCs 0.570–0.587).”
HumansROC analyses in CHARLS and NHANES
Research Square12 Oct 2026Preprint
TyG-WWI
upin humans1OR 1.08
1 study
TyG-WWI
upin humans1OR 1.08
TyG-WWI is associated with colorectal tumors in humans (OR 1.08, 95% CI 1.06–1.11).
“TyG-WWI (OR = 1.08, 95% CI: 1.06–1.11)”
HumansCHARLS; fully adjusted logistic regressionn = 9,293
Research Square12 Oct 2026Preprint
TyG-HGB
upin humans1OR 1.28
1 study
TyG-HGB
upin humans1OR 1.28
TyG-HGB is associated with colorectal tumors in humans (OR 1.28, 95% CI 1.20–1.36).
“TyG-HGB (OR = 1.28, 95% CI: 1.20–1.36)”
HumansCHARLS; fully adjusted logistic regressionn = 9,293
Research Square12 Oct 2026Preprint
TyG-CI
upin humans1OR 2
1 study
TyG-CI
upin humans1OR 2
TyG-CI is associated with colorectal tumors in humans (OR 2.00, 95% CI 1.60–2.50).
“TyG-CI (OR = 2.00, 95% CI: 1.60–2.50)”
HumansCHARLS; fully adjusted logistic regressionn = 9,293
Research Square12 Oct 2026Preprint
Triglyceride-glucose index
upin humans1OR 3.98
1 study
Triglyceride-glucose index
upin humans1OR 3.98
Triglyceride-glucose index is associated with colorectal tumors in humans (OR 3.98, 95% CI 2.66–5.94).
“In CHARLS, fully adjusted models showed strong associations for TyG (OR = 3.98, 95% CI: 2.66–5.94)”
HumansCHARLS; fully adjusted logistic regressionn = 9,293
Research Square12 Oct 2026Preprint
Trial sponsors
Company1 trialPhase 1/2325 people
Novartis Pharmaceuticals Corporation
Company1 trialPhase 1/274 people
1 trialPhase 450 people
1 trialPhase 230 people
1 trialPhase 1/249 people
1 trialPhase 1/215 people
Funding
4 grants since 2024National Cancer InstituteUS$3.1m
PROSPECT: Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
National Cancer InstituteBroad InstituteUS$315.7k2024–2026
PROSPECT: Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
National Cancer InstituteHarvard UniversityUS$614k2024–2026
MGH- PROSPECT: Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
National Cancer InstituteMassachusetts General HospitalUS$681.2k2024–2026
PROSPECT: Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
National Cancer InstituteKing's College LondonUS$333.3k2024–2026